Groundbreaking Dual‑Target CAR‑T Therapy Shows Promise in Recurrent Glioblastoma

By Sacred Leaves Global Medical News 

For two decades, glioblastoma multiforme (GBM), the most aggressive primary brain cancer, has defied major therapeutic advances. However, a recent Phase I trial, combining Gilead Sciences' Kite unit and University of Pennsylvania, marks a breakthrough. A dual‑target CAR‑T therapy, administered directly into cerebrospinal fluid, achieved tumor shrinkage in 62% of recurrent GBM patients—unusual for such a resilient cancer Reuters+10Reuters+10Larvol Delta+10.

Mechanism & Innovation

Unlike conventional therapies focusing on a single antigen, this dual-target approach neutralizes:

• EGFR (expressed in ~50–60% of GBM cases),
  
  
• IL‑13Rα2 (found in ~75%)
  
  

This strategy addresses tumor heterogeneity, a major barrier to efficacy in solid tumors MedPathFrontiers.

The CAR‑T cells, engineered from the patient’s own T‑cells, are delivered intrathecally—directly to the tumor’s environment—bypassing the blood-brain barrier and promoting more effective targeting Cell+14ecancer+14Reuters+14.

Clinical Findings

• Trial included 18 recurrent GBM patients, 13 had measurable tumors.
  
  
• 62% (8/13) showed significant tumor shrinkage Newsroom+11Reuters+11Larvol Delta+11Penn Today+5ecancer+5The ASCO Post+5.
  
  
• 11% remained disease-stable beyond 6 months; 43% survived past 12 months, a stark improvement against the usual 6–10‑month prognosis Larvol Delta+9ecancer+9MedPath+9.
  
  
• One patient exhibited 16 months of stable disease MDPI+12Reuters+12MedPath+12.
  
  

These results were discussed at ASCO 2025 and published in Nature Medicine STAT+10Reuters+10Penn Today+10.

Safety & Future Directions

• Adverse events (Grade 3 neurotoxicity) occurred in ~56%, but were manageable within clinical protocols The ASCO Post+3ecancer+3MedPath+3.
  
  
• An upcoming cohort will receive multiple doses to improve durability and response.
  
  
• Plans are underway to evaluate this therapy in newly diagnosed GBM patients, where early intervention could enhance outcomes MedPath+14ecancer+14MedPath+14.
  
  

Why It Matters

1. Addresses Solid Tumor Hurdles
   Dual-target design and intrathecal delivery overcome key challenges: tumor diversity and BBB penetration—issues that stymie CAR-T therapies in solid cancers MedPath+2ecancer+2Penn Today+2MedPath.
   
   
2. Promising Survival Signals
   Nearly half of patients exceeded 12 months survival—significantly above historical norms MedPath+1Reuters+1Penn Today+3ecancer+3The ASCO Post+3.
   
   

Blueprint for Broader Application

If validated in larger trials, this method could become a model for CAR‑T against other resistant solid tumors.